A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Lilly

Status and phase

Begins enrollment this month

Phase 1

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: LY3209590

Study type

Interventional

Funder types

Industry

Identifiers

NCT06362265

18437

I8H-MC-BDDB (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

Enrollment

22 estimated patients

Sex

All

Ages

10 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening

Exclusion criteria

Have had a severe hypoglycemia in the past 6 months
Have a history of renal impairment
Have had a blood transfusion or severe blood loss within last 90 days
Have had a significant weight gain or loss in the last 90 days
Have a history of an active or untreated malignancy
Are receiving or received systemic glucocorticoid therapy
Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product